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Abstract: The biopharmaceutical industry has traditionally been the key link between basic biomedical discovery and 
novel medicines. Today, the industry faces numerous challenges including the broad agreement that the current clinical 
trial system is inefficient and flawed. Most challenges are worsened by the inability of the stakeholders to work colla-
boratively. Over the last decade, many cooperative efforts to transform clinical research have been launched, but a sys-
temic solution has not been envisioned. A systems approach, including the application of systems engineering principles, 
has been used in other sectors and proposed for use in healthcare and medicines development. Clinical research, when 
looked at in systems terms, can be defined as an open system involving patients, investigators and associated staff, 
regulators, sponsors and stakeholders interconnected through a series of processes to bring effective and safe medicines 
into the market. ACRES is a global nonprofit organization with a mission of creating a multi-sector alliance of individuals 
and institutions collaborating on building a shared global system for clinical research excellence. A fundamental element 
of the ACRES system includes a global network of high-performing research sites interconnected through a shared 
information technology platform, with standardized policies and operational procedures and a robust, secure database to 
support performance, quality and safety. Five core initiatives address the larger mission and are currently ongoing. De-
liverables will roll out over 2015–2018. Positive reception to the concept, vision and goals among critical stakeholders, 
and a steady influx of strategic allies willing to work collaboratively demonstrates the strong pull exerted by the vision of 
a global system. However, due to the undertakings’ scope and complexity, challenges remain. Recognition that effective 
shared collaboration is the best long-term option among stakeholders and the general public constitutes a powerful in-
centive for ACRES contributors and strategic allies to keep working and make it happen. 
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1. Introduction: Why is a Systems Approach 
Needed? 
he biopharmaceutical industry has traditionally 
been the key link between basic biomedical 
discovery and the emergence of novel medi-
cines. Today, the industry faces a number of ongoing 
and emerging challenges, including technical know-
ledge gaps, limitations in clinical testing, lowered pro-
ductivity, higher development costs, increased regu-
latory requirements, growing payer pressures, patent 
expiration and an overall lack of openness and public T 
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trust[1–4]. 
Most large biopharmaceutical companies are com-
pensating for this by shifting to alternatives such as 
mergers and acquisitions of other, often smaller, com-
panies, outsourcing, and fixed cost and personnel re-
ductions, as well as broader collaboration with aca-
demia, contract research organizations and nonprofit 
institutions. An increased focus on growing new and 
emerging market revenue streams, including persona-
lized medicine and rare diseases, is also surging. A 
more prominent role for the patient in designing re-
search and implementing trials is under discussion in 
many ways. Countries from the emerging world are 
increasingly involved in the global medicines develop-
ment process, and this is reflected in the climbing 
number of publications and data supporting regulatory 
submissions worldwide. In terms of technological so-
lutions alone, local and regional enterprises are also 
blooming[4,5].  
Clinical trials constitute the largest single compo-
nent of the R&D budget of the biopharmaceutical in-
dustry, representing nearly 40% of the R&D expenses 
of major companies. However, there is broad agree-
ment that the current clinical trial system is inefficient 
at best, and deficient and wasteful in other regards[6].  
Currently, each clinical trial is typically organized 
de novo, requiring substantial effort, cost, and time. 
Sponsors and contract research organizations (CROs) 
must identify clinical investigators and assemble mul-
ti-investigational teams. Protocols must be written, 
approved by regulators and submitted to each of many 
institutions, where approval by ethics committees and 
contract negotiators can take several months, without 
necessarily improving the scientific and ethical 
aspects of the study or the protection of study 
participants. A wealth of published research details the 
inefficiency in the clinical research process. A recent 
evaluation by the Institute of Medicine[7] assessed the 
challenges affecting the US clinical trials enterprise 
including: 
• Increasingly high costs, lengthy delays and in-
consistencies associated with elaborate admin-
istrative procedures established by risk-averse 
research organizations; 
• Decline in the number of medical researchers, 
coupled with the lack of stable funding and 
employment; 
• Low rates of enrollment and retention of people 
in clinical trials coupled with lackluster re-
cruitment efforts by physicians and other 
healthcare providers, so that many planned tri-
als are not completed; 
• Inconsistent adoption of clinical trial results by 
healthcare providers, payers and patients in 
making decisions related to individual patient 
care. 
On the other hand, the most common deficiency 
codes reported by the US FDA following clinical in-
vestigator site inspections are Failure to follow 
investigational plan and inadequate and inaccurate 
records[8]. About one out of three investigators do not 
adhere to the investigational plan and one out of four 
investigators do not keep accurate records. There has 
not been any improvement in these findings for more 
than two decades[9].  
Thus, errors are repeated time and time again in re-
search across the world with poor organizational 
learning and much wasted effort. 
The lack of an adequately sized and appropriately 
trained multi-professional workforce both in the in-
dustry and in the clinical research field is also a sig-
nificant part of the problem. Larger pools of highly 
trained, competent professionals are needed to in-
crease the industry’s ability to safely and effectively 
bring new medicines to the marketplace. The necessity 
for further competency based education and training 
has been identified all over the world[10–14].  
Many of the challenges outlined are worsened by 
the inability of the biopharmaceutical industry, gov-
ernments and regulatory agencies, academic research-
ers, and the healthcare community to work together 
collaboratively. This makes it difficult to fill these 
gaps and create not only effective clinical trial profes-
sionals but also powerful networks and realistic trial 
designs.  
Over the last decade, many collaborative efforts to 
transform clinical research have been launched, but a 
systemic solution has not been envisioned. Each ini-
tiative—including the Clinical Trials Transformation 
Initiative[15] the European Innovative Medicines Ini-
tiative[16], the Multi Regional Clinical Trials Initia-
tive (MRCT)[17], CDISC[18] and most recently Trans-
Celerate[19] was designed to address one specific 
aspect of the clinical trial chain rather than the entire 
endeavor. 
Therefore, it is self-evident that a comprehensive, 
high-performing system that integrates key stakehold-
ers on a sustained basis has been regarded as neces-
sary[7].  
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2. What is a Systems Approach?   
A systems approach, including application of systems 
engineering principles and thinking, has been used in 
other sectors ranging from transportation and defense 
to energy, electronics and information technology. 
These sectors recognized long ago the value and im-
portance of systems thinking and have effectively ap-
plied it beneficially in their respective domains. Like-
wise, the concepts of systems, systems approaches and 
systems engineering have been proposed as possible 
solutions to address complex problems in public 
health[20] and drug discovery and development[21,22]. 
Despite well-intentioned patchy efforts, systematic 
application has not occurred. 
An analogy to the airline transportation system is 
among the easiest to understand as it encompasses 
everything from scheduling, reservations, flight logis-
tics and baggage-handling to air traffic control, com-
munications, financial management and regulatory 
simplification. 
Every system is delineated by its spatial and tem-
poral boundaries, surrounded and influenced by its 
environment, described by its structure and purpose 
and expressed in its functioning. Some systems share 
common characteristics[23] including: 
• Structure: it contains parts (or components) that 
are directly or indirectly related to each other; 
• Behavior: it exhibits processes that fulfill its 
function or purpose; and can be categorized as 
either fast or strong, as related to its surround-
ings; 
• Interconnectivity: the parts and processes are 
connected by structural and/or behavioral rela-
tionships. 
The term “systems thinking” denotes a methodolo-
gy applicable to a wide range of endeavors. Basically, 
systems thinking focuses on interactions and interde-
pendencies that together define an integrated whole, 
from control points to communications. These are 
viewed from the perspective not only of technology 
but human behavior—the “hard” and the “soft” di-
mensions, as it were. But most fundamentally, a sy-
stems approach is the diametric opposite of “silos”—
the fragmentation of operations, functions, and stakeh-
olders acting in isolation, so typical in biomedical 
R&D and healthcare, under a misguided reductionist 
approach[23].  
A feature common to systems thinking is leverag-
ing data-rich environments to probe their complexities 
and create integrating solutions that cut across opera-
tions, functions, and stakeholders. The key properties 
of a system, compared with each of its elements or 
parts, are its emerging patterns and behavior[23]. 
Systems thinking is an approach to problem solving, 
viewing: “problems” as parts of an overall system in 
contrast to isolating specific parts, outcomes or events 
that result in further, and unintended, consequences. 
Systems thinking is a framework that is based on the 
understanding that the component parts of a system 
can best be understood in the context of relationships 
with each other and with other systems, rather than in 
isolation. Systems thinking focus on the cyclical and 
dynamic, and on feedback mechanisms, rather than on 
linear and static cause and effect[24].  
Clinical research in medicines development can be 
defined as an open system involving patients, inve-
stigators and associated staff, regulators, sponsors, 
research sites, and so on as components interco-
nnected through a series of processes that aims to 
introduce and maintain effective and safe medicines in 
the market. In effect, all who work in clinical research 
have a defined role which influences the system 
sometimes in ways many do not realize. 
A sound “systems approach” is thus needed to bring 
together all of the stakeholders involved in clinical 
research to identify and strengthen the interconnec-
tions among component parts, improve the attendant 
processes, and enhance transparency across the system. 
This in turn will help to overcome the current barriers 
to cost-effectiveness, efficiency, safety and ethical 
behavior impacting decision-making at all levels and 
appropriate management of risks. 
3. What is ACRES? 
ACRES (Alliance for Clinical Research Excellence 
and Safety) is a multi-sector alliance of innova-
tion-minded individuals and organizations working 
collaboratively to build a shared global system for 
clinical research excellence. ACRES is a global non-
profit organization operating in the public interest 
based in Cambridge, MA, USA.  
Currently, it involves over 60 strategic allies that 
are committed to change. ACRES allies include not 
only sponsors and CROs, but also academic institu-
tions, professional associations and societies, tech-
nology vendors, service providers, ethics committees, 
research site networks, patient groups and cross-sector 
collaborations. Such a unique alliance has never been 
established before. 
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In addition, well over 90 executives, senior man-
agers, and subject matter experts from all over the 
world participate in the range of ACRES Foundation 
Initiatives (such as Site Accreditation and Standards, 
Safety, and Technology Integration), working together 
to achieve the ACRES vision by applying effective 
systems thinking to the clinical research enterprise in 
the spirit of volunteerism. 
One level of the ACRES integrated system for 
clinical research envisions a global network of high- 
performing research sites interconnected through a 
shared information technology platform, with stand-
ardized policies and operational procedures and a 
robust, secure database to support mission-critical 
analysis of performance, quality and safety within an 
enterprise-wide culture of safety (Figure 1). 
 
 
 
Figure 1. The Core concept of ACRES (cite from www. acres-
global.net). 
 
Such an integrated system operates under the 
premise of Accountable Research™, complementary 
to Accountable Healthcare, which implies the 
development, recognition and acceptance of principles 
of individual and organizational social responsibility 
for conducting biomedical research in a manner that 
assures the interest and well-being of research subjects, 
the safety of therapeutic products, the integrity of all 
research data and the effectiveness of operational 
processes to benefit all stakeholders worldwide. 
The ACRES mission has anticipated four essential 
domains: site development, support and sustainability, 
quality and safety management, safety and pharmaco-
vigilance, and information technology. Projects and 
objectives were devised within each of the operational 
domains leading to the five Foundation Initiatives, 
each with specific goals, deliverables and timelines.  
An overview of ACRES Foundation initiatives and 
some initial deliverables follows. It is important to 
emphasize that they are integrated, that is, each im-
pacts the others as a reflection of the systems thinking 
approach. 
4. ACRES Foundation Initiatives 
Five core initiatives are currently underway: 
• Site Accreditation and Standards (SASI) 
• Site Optics and Quality Informatics (SOQI) 
• Product Safety Culture (PSCI) 
• Global Ethical Review and Regulatory Innova-
tion (GERI) 
• Quality Assurance and Safety (QASI) 
Site Accreditation and Standards (SASI): Site accre-
ditation and certification of the clinical research teams 
are key elements for Accountable Research™. This 
initiative addresses the need for a cohesive, effective 
approach to promoting and sustaining excellence of 
clinical research sites.  
Currently, uniform standards for clinical research 
sites and independent third-party accreditation do not 
exist. Yet such standards are required to objectively 
assess and recognize sites of excellence and to ensure 
their sustainability. The burgeoning costs of conduct-
ing clinical trials include inefficiencies that partly re-
sult from the lack of uniform standards and accredita-
tion support infrastructure. Uniform standards further 
ensure connectivity and interoperability essential to 
establishment of an effective global network.   
The implementation of SASI is now in its third 
phase. The first phase surveyed the current landscape 
and gathered perspectives from a wide range of 
stakeholders from the USA, Europe, Asia and Latin 
America. Seven standard domains were identified: 
personnel, facilities, management, information tech-
nology, quality management, research integrity and 
patient engagement. The specific standards pertaining 
to each domain are currently under preparation and a 
pilot test will follow. The final standards are to be 
available by December 2016.  
Related ongoing projects within SASI or impacting 
SASI as part of the ACRES collaboration with other 
strategic allies include: 
• Development of harmonized core competencies 
for clinical research professionals in collabora-
tion with a range of professional associations 
and academic institutions gathered under the 
Joint Task Force for Clinical Trial Competen-
cy[11]. The core competencies are to be used for 
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the accreditation of postgraduate education and 
training programs as well as to define job port-
folios and job profiles. An international valida-
tion exercise is currently ongoing. 
• Preliminary identification of levels of sites as 
related to the complexities required of the var-
ious phases of clinical trials (Table 1). A vali-
dation process would be developed in align-
ment with SASI phase III.  
• Creation of a “universal” developmental model 
of electronic data flow mapping clinical trial 
information exchanges (from trial design 
through regulatory approval). The project also 
promotes a comprehensive integration of the 
model into operational systems at all levels of 
the health sciences and medicines development 
enterprise. 
• Development of a “trust framework” within the 
global system to ensure a secured information 
exchange: The pilot experience with strategic 
allies has been completed.  
• Development of a “menu” of ally-provided site 
services to support standards adherence and 
accreditation and to promote operational ex-
cellence and sustainability.  
• Development of a neutral third party accredita-
tion oversight entity to oversee and “authorize” 
accrediting bodies, since ACRES will not be an 
accrediting body. This recognizes that different 
countries have, or will have, various accredita-
tion approaches (some governmental, some 
private, and some a combination). Accredita-
tion of as many as 150,000 sites globally will 
likely require multiple accrediting entities, each 
of which themselves will require accreditation 
to ensure the integrity and effectiveness of the 
accreditation process. The accreditation entity 
would be the custodian of the standards and 
house the process for accreditation. 
• Creation of an innovative “dynamic accredita-
tion” process: different from traditional accredi-
tation models, this approach analyzes real-time 
performance, quality, and safety data according 
to established metrics to determine whether a 
site is operating in a manner consistent with the 
accreditation standards, optimizing perform-
ance and regulatory and ethical compliance. 
Dynamic accreditation utilizes information gene-
rated during the routine clinical trials process, 
largely eliminating administrative burdens at-
tendant to most accreditation processes while 
improving timeliness and effectiveness. 
• International expansion, through the appoint-
ment of country and regional coordinators 
 
Table 1. Minimum criteria for site qualification 
Parameter Site Level I Site Level II Site Level III Site Level IV 
Studies conducted PMS/PASS/Comparative effectiveness Phase IV or Phase IIIb 
Phase II-III 
Investigator initiated 
Phase I-III 
IIS 
Study end-points 
Patient reported 
Laboratory 
Surrogate markers 
Level I + 
Novel biomarkers 
Level II + 
Not validated biomarkers 
Level III + 
Exploratory biomarkers 
Number and complexity of 
Procedures/Protocol Few Intermediate High 
High/very high/Proof 
of Concept 
Expected safety profile No specific safety issues/ Well known AE profile 
Level I + 
Unknown SAEs 
Level II + 
Unknown AE/SAE 
First in humans 
Unknown SAEs/AEs 
Study duration Days to months Weeks/Months Days to months Days to months 
Patient demographics Outpatients Outpatients/Inpatients Outpatients/Inpatients Out and inpatients 
Average # of studies con-
ducted/year <5 <10 <15 >15 
Site technological facilities Few; standard of care AQ (Standards/Standard) Few; standards of care 
Level II + advanced 
technologies 
Advanced technologies 
Genomics 
IT communication facilities  Acceptable Acceptable Good Excellent 
Expertise in diverse medical 
specialties Single 2–3 medical disciplines Several (5–10) >10 
GCP compliance in the past 5 
years <1 audit 
<3 audits and no critical 
audit findings 
< 5 audits and no critical 
audit findings 
>5 audits and no criti-
cal audit findings 
Investigator and staff certifi-
cation No No Yes Yes 
Emergency medical care 
available  No Yes Yes Yes 
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committed to creating awareness of the ACRES 
new system and helping in the creation of the 
country site networks. Activities include the 
local site identification, recruitment and affilia-
tion as well as interface with the country regu-
latory agencies. An ACRES organization is al-
ready operative in Japan, and frameworks are 
being established in Korea, Germany and Bul-
garia, among other countries (see www.acr-
esglobal.net). 
Site Optics and Quality Informatics (SOQI): This 
initiative addresses the need to ensure interoperability 
across the global network of sites and to optimize ap-
plication and exploitation of technology. In addition to 
standards, the system will require a robust and sup-
portive information technology platform that can be 
shared on an enterprise-wide basis. The following in-
frastructure projects are underway: 
• Creation of a Technology Consortium, aimed at 
developing a shared, universal interface engine 
that will allow sites, sponsors, contract research 
organizations, regulators, other providers of 
products and services as well as patients to 
communicate and collect, archive and share 
information in a secure manner. The partners of 
the consortium are currently developing models 
and technical specifications, seeking to com-
plete the initial application for testing and 
evaluation by the end of 2015, with anticipated 
deployment in 2016. 
• The ACRES BlueCloud which allows the access 
and management of information in real time 
from multiple sources through application pro-
gram interfaces (APIs). In short, it is an 
integration system that allows healthcare and 
clinical research providers to consolidate and 
deliver information in real time from a common, 
secured, compliant and industry-neutral single 
location for the purpose of Accountable 
Research™. The timelines run in parallel to the 
consortium’s. 
Product Safety Culture (PSCI): This initiative exp-
lores the application of safety engineering, human 
factors, and organizational science insights, tools, and 
techniques to design safe systems for clinical research 
with a particular focus on training and education. In 
addition, it is examining better pharmacovigilance 
practices not covered by any guidelines or regulations. 
Primary projects are underway that integrate with oth-
er ACRES efforts, including: 
• Using a model of causation (STAMP or Sys-
tems-Theoretic Accident Model and Processes) 
to investigate whether and how it might im-
prove the design, operation, and management 
of the subsystem for early phase pharmacok-
inetics and pharmacodynamics research inclu-
ding trials (Phase I). This may help in creating 
a common roadmap for safe early development 
using safety engineering methods and applying 
insights from the emerging interdisciplinary 
field of Human Factors which focuses on how 
psychological dimensions impact making judg-
ments and decisions. 
• By working with IT allies, promoting creation 
of a unified safety database whereby all data-
sets relevant for patient safety will be integ-
rated through an open access clinical research 
safety informatics subsystem. 
• Establishing standards for safe and effective 
outsourcing in pharmacovigilance. 
• Public outreach in cooperation with media out-
lets and other organizations, focused on intera-
ctive education and training of the public and 
journalists reporting on biomedical research by 
discussing safety-related matters and other key 
issues related to clinical trials and health with 
the general public. An Accountable Research 
blog has been created in cooperation with 
Hearst Media (http://blog.mysanantonio.com/ 
acresaccountableresearch/2015/04/accountabili-
ty-in-health-health-care-and-biomedical-rese
arch/). 
Global Ethical and Regulatory Innovation (GERI): 
This initiative addresses the need for ethical and 
regulatory global standardization (beyond ‘harmoniza-
tion’), the difficulties in complying with complex 
regulations and guidance and the need for leveraged 
interaction between regulators and other key stake-
holders to support innovation and build trust. Many 
agree that the needs of patients should dominate all 
activities (‘patient-centricity’) although how that 
should happen is unclear. The following initial 
projects are underway: 
• Mapping global efforts for regulatory simplifi-
cation and innovation and deriving implement-
able solutions from ethical and efficiency pers-
pectives beginning with development of a glos-
sary and focusing on informed consent in the first 
in a series of a multi-stakeholder symposium  
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consultations. 
• Following agreement on guiding systems prin-
ciples for informed consent, extrapolating 
and establishing these to ethical and regula-
tory needs for globally accredited research 
sites, and aligning standards for optimizing 
transparency and increased trust in communi-
cation and cooperation among stakeholders 
related to SASI and PSCI. 
Quality Assurance and Safety Initiative (QASI): This 
initiative include methods for remote risk-based 
monitoring and audit sharing as well as addressing the 
unique needs of alternative forms of conducting 
clinical trials in light of scientific discoveries, such as 
development of genomics and proteomics, and per-
sonalized medicine’s impact on clinical research. Cre-
ation of a single repository of audit findings will con-
tribute to organizational learning.  
5. ACRES Impact, Challenges and Opportunities 
ACRES was incorporated as a nonprofit organiza- 
tion in 2012, although the original concept dates to 
over a decade prior. This timing was on target, based 
on the accumulation of needs globally, and recognition 
by biomedical R&D stakeholders and critics. 
 
ACRES has had a favorable reception to its concept, 
vision and goals among critical stakeholders including 
regulatory agencies, pharmaceutical companies, aca-
demic sites, professional organizations, technology 
providers and the public. A steady influx of strategic 
allies willing to partner and volunteer to help achieve 
the ACRES vision and collaborate in devising the 
system is ongoing, and is further evidence of the tim-
ing being appropriate (Figure 2).  
Differing in intent from trade associations, profes-
sional societies, and other forms of nonprofit organi-
zations is also an important dimension of ACRES’s 
broad-based and growing acceptance. 
Nevertheless, given the scope and complexity of its 
undertaking, challenges remain in constructing the 
global system as visualized by the ACRES vision, in 
particular: 
• Conveying the conceptualization of the system 
and its parts in contrast to what currently exists 
and overcoming organizational inertia, apathy 
and resistance to change. 
• Demonstrating the feasibility of building such a 
system in an effective and efficient manner in a 
time of scarce resources and changing regula-
tions. 
 
 
 
Figure 2. The components of the ACRES system. 
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• Expanding the visibility and clarity of the 
ACRES message among and across the mul-
tiple stakeholders. 
• Continuing to generate sufficient resources, 
both financial and in-kind, to support mission 
critical initiatives and the basic ACRES infra-
structure to supplement the significant volun-
teer and donor resourcing that ACRES has en-
joyed from inception. 
• Confusion with other initiatives that could be 
seen as competing or overlapping, leading to 
ACRES being perceived as redundant even 
though ACRES itself is unique. Recent bench-
marking — as well as meetings with a range of 
such initiatives—has proven valuable for all 
parties, ensuring both the value of and best 
areas for cooperation, something ACRES is 
striving to accomplish[25]. 
Ways of overcoming these challenges continue to 
evolve and thus ACRES continues to gain mul-
ti-stakeholder support. No less significant, ACRES 
presence and efforts have had a positive impact on 
other reform efforts, including both adoption and 
adaptation by specific stakeholder groups as part of 
their own respective missions (but independent from 
an overall intended system as yet). In addition, there is 
no downside or negativity so long as ACRES remains 
focused on science and patients’ needs because 
ACRES is committed to learning from all of its expe-
riences. 
ACRES has also worked diligently to establish re-
lationships with national regulatory agencies as well 
as with pharmaceutical companies and global profes-
sional associations, since endorsement and acceptance 
by these constituents are critical for the sustainability 
of the proposed system. 
From the economic perspective, the case for a 
global system approach is solid and self-evident. Es-
timated gains in efficiency, time to market, clinical 
trial performance, safety, regulatory burden, and re-
duced waste can reach several billions of dollars. 
Already, organizations using just small parts of the 
ACRES BlueCloud are realizing that millions of 
dollars in savings can be achieved, but further pilot 
and confirmatory experiences will be necessary once 
the foundations of the system are in place. 
The ACRES model for a financially self-sustaining 
organization is based on a range of revenue streams 
related to the products and services of the Foundation 
Initiatives. 
Deliverables from the various ACRES Initiatives 
are anticipated during the period 2015–2018. Pilot 
testing for implementation is an essential part of the 
process for assuring integration into the planned sys-
tem.  
Engagement with research sites is critical and thus 
efforts for recruitment and qualification will be a pri-
mary objective in the short term as part of a staged 
implementation plan leading to the formal site accre-
ditation in the medium term. 
Implementation of ACRES is indeed a complex and 
challenging undertaking and significant anticipated 
obstacles are being addressed. Realization that an ef-
fective shared collaborative system is the best 
long-term option among stakeholders and the general 
public constitutes a powerful incentive for the ACRES 
contributors and strategic allies to keep working to 
make it happen. The need to demonstrate leadership 
and restore passion into clinical research has never 
been greater. 
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